10-K: Coeptis Therapeutics Reports 2024 10-K Filing: Focus on Cell Therapy Technologies and Strategic Partnerships

Coeptis Therapeutics Holdings, Inc. files its 2024 10-K, highlighting its focus on cell therapy technologies, strategic partnerships, and financial results.

Summary

• Coeptis Therapeutics Holdings, Inc. filed its 10-K report for the fiscal year ended December 31, 2024.
• The company is focused on developing cell therapy technologies for cancer and other diseases.
• Coeptis operates through subsidiaries including SNAP Biosciences, Inc., GEAR Therapeutics, Inc., Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., and Coeptis Pharmaceuticals, LLC.
• The company is exploring strategic opportunities to expand its GEAR development platform and cellular immunotherapy assets.
• Coeptis is pursuing a growth strategy focused on portfolio optimization, strategic partnerships, and business development.
• The company had seven employees as of the end of the reporting period.
• A Standby Equity Purchase Agreement (SEPA) was entered into in November 2024, allowing the company to sell up to $20 million of common stock to Yorkville, subject to certain limitations.
• The company is considered an emerging growth company and is taking advantage of reduced disclosure requirements.
• The company incurred a net loss of $10,877,412 for the year ended December 31, 2024, and had an accumulated deficit of $98,233,673.
• The company had cash of $532,885 as of December 31, 2024.
• The company needs to obtain financing in order to continue operations and pursue strategic transactions.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with significant losses and reliance on future financing, tempered by strategic initiatives and potential partnerships.

Positives

• The company is actively seeking partnerships and strategic collaborations.
• The company has platform technologies with expansive capabilities.
• The company has been granted an extension through January 15, 2025, to regain listing compliance with Nasdaq.
• The company has regained compliance with the minimum bid price of $1.00, and that Nasdaq has determined to continue the listing of the Companys securities.

Negatives

• The company has a history of losses and expects to incur losses in the future.
• There is a substantial doubt about the company's ability to continue as a going concern.
• The company needs to obtain financing in order to continue operations.
• The company may not be able to successfully implement its growth strategy.
• The company may not be able to maintain its listing on the Nasdaq Capital Market.

Risks

• The company may not be able to successfully implement its growth strategy on a timely basis or at all.
• The company may have difficulties managing its anticipated growth, or it may not grow at all.
• The company has a history of losses, expects to incur losses in the future, and may not be able to achieve or maintain profitability.
• The company may not be able to initiate and complete preclinical studies and clinical trials for its product candidates.
• The company may not be able to obtain and maintain the third-party relationships that are necessary to develop, commercialize and manufacture some or all of its product candidates.
• The company needs to obtain financing in order to continue its operations.
• The drug development and approval process is uncertain, time-consuming and expensive.
• Competition in the biotechnology and pharmaceutical industries may result in competing products, superior marketing of other products and lower revenues or profits for the company.
• Protecting and defending against intellectual property claims may have a material adverse effect on the company's business.
• The company may not be able to maintain its listing on the Nasdaq Capital Market.
• There is a substantial doubt about the company's ability to continue as a going concern.

Future Outlook

The company expects to continue to generate operating losses and experience negative cash flow from operations at least through the end of 2024. Management does not expect the Company to generate any significant revenue for at least the next year, during which time drug development will continue toward the goal of commercializing, through a partnership or otherwise, one or more of the Companys target products or technologies.

Industry Context

The company operates in the competitive biotechnology and pharmaceutical industries, facing competition from companies with greater resources and experience.

Management Changes

Related Party Transactions

• On April 17, 2024, the Company entered into an unsecured note agreement with a related party in the principal amount of $500,000 together with interest at 10 %, with a maturity date of September 30, 2024.
• On June 3, 2024, the Company and the related party agreed to convert the note agreement in full, both principal and interest, to equity in connection with the Companys Series A Preferred Stock offering.
• Christopher Calise, a current member of our Board of Directors, participated in the offering personally and through an entity controlled by him.

Stakeholder Impact

• Shareholders face the risk of dilution from potential equity sales under the SEPA.
• Employees face uncertainty due to the company's financial challenges and potential need for cost-cutting measures.
• The company's ability to develop and commercialize its product candidates depends on securing additional financing and maintaining key partnerships.

Next Steps

• The company will continue to evaluate, prioritize, optimize, and make appropriate changes in its pipeline portfolio.
• The company will focus on expanding its existing pipeline through establishing strategic partnerships with companies that have interesting products and technologies.
• The company is actively seeking partnerships and/or strategic collaborations with companies that share in its vision and therapeutic focus.

Key Dates

Keywords

cell therapy, strategic partnerships, biopharmaceutical, GEAR-NK, SNAP-CAR, clinical trials, financing, CD38, warrants, Nasdaq